2024/0900 - BICTEGRAVIR + EMTRICITABINA + TENOFOVIR ALAFENAMIDA [50 + 200 + 25 MG CÁP/ COMP]
TED · 521471-2026Award noticeawardedNo deadline given
Who already wins at this buyer
Firms with recorded awards from Unidade Local de Saúde Santa Maria, E.P.E. in this tender’s CPV categories — the incumbents you are bidding against.
| Firm | Wins | Awarded | Last win |
|---|---|---|---|
| ROCHE Farmacêutica Química, LDA | 20 | — | 2026-07-28 |
| GILEAD SCIENCES, LDA | 17 | — | 2026-07-28 |
| SANOFI-PRODUTOS FARMACÊUTICOS,LDA | 13 | €1,569,649 | 2026-07-28 |
| NOVARTIS FARMA - PROD.FARM SA | 9 | — | 2026-06-30 |
| TAKEDA-Farmaceuticos Portugal, Lda | 8 | €554,760 | 2026-07-28 |
Full buyer profile: what Unidade Local de Saúde Santa Maria, E.P.E. buys and who wins it →
CPV codes
33600000 Medical equipment & pharmaceuticalsDescription
BICTEGRAVIR + EMTRICITABINA + TENOFOVIR ALAFENAMIDA [50 + 200 + 25 MG CÁP/ COMP]
Similar tenders
Closest by meaning — across languages, via embeddings.
| Published | Title | Buyer | Match |
|---|---|---|---|
| 2026-07-28 | 2024/0900 - BICTEGRAVIR + EMTRICITABINA + TENOFOVIR ALAFENAMIDA [50 + 200 + 25 MG CÁP/ COMP] | Unidade Local de Saúde Santa Maria, E.P.E. PT | 100% |
| 2026-07-07 | 2024/0900 - DOLUTEGRAVIR + ABACAVIR + LAMIVUDINA [50 MG + 600 MG + 300 MG CÁP/COMP] | Unidade Local de Saúde Santa Maria, E.P.E. PT | 95% |
| 2026-06-30 | 2024/0900 - DOLUTEGRAVIR + RILPIVIRINA [50 MG + 25 MG CÁP/ COMP] | Unidade Local de Saúde Santa Maria, E.P.E. PT | 94% |
| 2026-05-12 | 2024/0900 - LAMIVUDINA + DOLUTEGRAVIR [300 MG + 50 MG COMP] | Unidade Local de Saúde Santa Maria, E.P.E. PT | 94% |
| 2026-05-12 | 2025/1589 - MARIBAVIR [200 MG COMP] | Unidade Local de Saúde Santa Maria, E.P.E. PT | 93% |
| 2026-07-21 | 2023/0491 - ABEMACICLIB [150 MG CÁP/ COMP] | Unidade Local de Saúde Santa Maria, E.P.E. PT | 93% |